PharmaGap Adds to Patent Portfolio For GAP-107B8 Cancer Drug; Expands Claims
September 29 2011 - 8:43AM
Marketwired
PharmaGap Inc. (TSX VENTURE: GAP) (OTCBB: PHRGF) ("PharmaGap" or
"the Company") is pleased to announce the first of two provisional
patent applications with the United States Patent and Trademark
Office ("USPTO") covering the results of development of PharmaGap's
lead cancer drug GAP-107B8 during 2011 to date. These provisional
patent filings covering the GAP-107B8 formulations represent
significant steps forward in the Company's ability to realize value
from the Company's drug development program.
This filing, titled "Anti-Cancer Peptides and Uses Thereof",
addresses both the original and modified forms of GAP-107B8. The
modified version of GAP-107B8 has been created through the
application of commonly used drug formulation techniques in order
to advantageously adjust the molecular properties of GAP-107B8 to
enhance stability and biological activity of a drug compound while
maintaining its essential nature.
This filing also expands previous claims for GAP-107B8, and
specifically addresses methods of treating malignant ascites (a
severe and common morbidity occurrence in ovarian cancer and other
cancers listed below), of treating or preventing metastasis of a
cancer, and for the inhibition of Akt expression. Akt is a
serine/threonine protein kinase that plays a key role in multiple
cellular processes (cell motility and invasion, hormone
independence, and chemotherapy and radiation resistance) and has
been implicated as a major factor in many types of cancer,
including certain breast cancers, pancreatic cancers, colorectal
cancers, gastric cancers and ovarian cancers.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE: GAP), based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is
a novel peptide drug that has been shown to be highly cytotoxic to
numerous cancer types, including chemo-resistant cancers, in vitro.
For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.
Forward Looking Statements
This news release contains certain statements that constitute
forward-looking statements as they relate to the Company and its
management. Forward-looking statements are not historical facts but
represent management's current expectations of future events, and
can be identified by words such as "believe", "expects", "will",
"intends", "plans", "projects", "anticipates", "estimates",
"continues", and similar expressions. Although management believes
that expectations represented in such forward-looking statements
are reasonable, there can be no assurance that they will prove to
be correct.
By their nature, forward-looking statements include assumptions
and are subject to inherent risks and uncertainties that could
cause actual future results, conditions, actions or events to
differ materially from those in the forward-looking statements. If
and when forward-looking statements are set out in this news
release, PharmaGap will also set out the material risk factors or
assumptions used to develop the forward-looking statements. Except
as expressly required by applicable securities laws, the Company
assumes no obligation to update or revise any forward-looking
statements. The future outcomes that relate to forward-looking
statements may be influenced by many factors, including, but not
limited to: results of ongoing product testing and development;
regulatory approvals required to complete development of products;
ability to manufacture product at quality and scale for human use
on an economically sound basis; patient reimbursement by private
and public health insurance programs; unintended side effects of
products; competitive products; product liability; intellectual
property; reliance on key personnel; risks of future legal
proceedings; income tax matters; availability and terms of
financing; distribution of securities; effect of market interest
rates on price of securities, and potential dilution.
Note: Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has
approved or disapproved of the information contained herein. This
release contains forward looking statements that may not occur or
may change materially.
Contacts: PharmaGap Inc. Robert McInnis President & CEO
613-990-9551 bmcinnis@pharmagap.com
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Jun 2023 to Jun 2024